메뉴 건너뛰기




Volumn , Issue , 2008, Pages 775-827

Utilization of In Vitro Cytochrome P450 Inhibition Data for Projecting Clinical Drug-Drug Interactions

Author keywords

Adverse drug reactions (ADRs); Probe substrate selection; Reversible inhibition

Indexed keywords


EID: 84870204584     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470249031.ch22     Document Type: Chapter
Times cited : (5)

References (159)
  • 2
    • 0032522873 scopus 로고    scopus 로고
    • Incidence of adverse drug reactions in hospitalised patients
    • Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalised patients. JAMA 1998;279(15):1200-1205.
    • (1998) JAMA , vol.279 , Issue.15 , pp. 1200-1205
    • Lazarou, J.1    Pomeranz, B.H.2    Corey, P.N.3
  • 3
    • 34548480876 scopus 로고    scopus 로고
    • Evaluation of pharmacotherapy in geriatric patients after performing complete geriatric assessment at a diagnostic day clinic
    • Frankfort SV, Tulner LR, van Campen JPCM, Koks CHW, Beijnen JH. Evaluation of pharmacotherapy in geriatric patients after performing complete geriatric assessment at a diagnostic day clinic. Clin Drug Invest 2006;26(3):169-174.
    • (2006) Clin Drug Invest , vol.26 , Issue.3 , pp. 169-174
    • Frankfort, S.V.1    Tulner, L.R.2    van Campen, J.P.C.M.3    Koks, C.H.W.4    Beijnen, J.H.5
  • 4
    • 0027327987 scopus 로고
    • Epidemiology of drug-drug interactions as a cause of hospital admissions
    • Jankel C, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Safety 1993;9:51-59.
    • (1993) Drug Safety , vol.9 , pp. 51-59
    • Jankel, C.1    Fitterman, L.K.2
  • 6
    • 12544251868 scopus 로고    scopus 로고
    • Mechanistic basis of adverse drug reactions:the perils of inappropriate dose schedules
    • Shah RR. Mechanistic basis of adverse drug reactions:the perils of inappropriate dose schedules. Expert Opin Drug Safety 2005;4(1):103-128.
    • (2005) Expert Opin Drug Safety , vol.4 , Issue.1 , pp. 103-128
    • Shah, R.R.1
  • 7
    • 0031723235 scopus 로고    scopus 로고
    • Prediction of pharmacokinetic alterations caused by drug-drug interactions:metabolic interaction in the liver
    • Ito K, Iwatsubo T, Kanamutsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions:metabolic interaction in the liver. Pharmacol Rev 1998;50(3):387-411.
    • (1998) Pharmacol Rev , vol.50 , Issue.3 , pp. 387-411
    • Ito, K.1    Iwatsubo, T.2    Kanamutsu, S.3    Ueda, K.4    Suzuki, H.5    Sugiyama, Y.6
  • 8
    • 33750547308 scopus 로고    scopus 로고
    • CYP2C9 inhibition:impact of probe selection and pharmacogenetics on in vitro inhibition profiles
    • Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, Tracy TS. CYP2C9 inhibition:impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 2006;34(12):1966-1075.
    • (2006) Drug Metab Dispos , vol.34 , Issue.12 , pp. 1075-1966
    • Kumar, V.1    Wahlstrom, J.L.2    Rock, D.A.3    Warren, C.J.4    Gorman, L.A.5    Tracy, T.S.6
  • 9
    • 12244295474 scopus 로고    scopus 로고
    • Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolic data
    • Shou M. Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolic data. Curr Opin Drug Discov Dev 2005;8(1):66-77.
    • (2005) Curr Opin Drug Discov Dev , vol.8 , Issue.1 , pp. 66-77
    • Shou, M.1
  • 11
    • 18844410849 scopus 로고    scopus 로고
    • Predicting inhibitory drug-drug interactions and evaluating interaction reports using inhibition constants
    • Backmann KA, Lewis JD. Predicting inhibitory drug-drug interactions and evaluating interaction reports using inhibition constants. Ann Pharmacother 2005;39:1064-1072.
    • (2005) Ann Pharmacother , vol.39 , pp. 1064-1072
    • Backmann, K.A.1    Lewis, J.D.2
  • 12
    • 0029890375 scopus 로고    scopus 로고
    • Cisapride and fatal arrhythmia
    • Wysowsk DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 335(4):290-291.
    • (1996) N Engl J Med , vol.335 , Issue.4 , pp. 290-291
    • Wysowsk, D.K.1    Bacsanyi, J.2
  • 13
    • 33748946044 scopus 로고    scopus 로고
    • Prediction of in vivo drug-drug interactions from in vitro data:factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4
    • Brown HS, Galetin A, Halifax D, Houston JB. Prediction of in vivo drug-drug interactions from in vitro data:factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 2006;45(10):1035-1050.
    • (2006) Clin Pharmacokinet , vol.45 , Issue.10 , pp. 1035-1050
    • Brown, H.S.1    Galetin, A.2    Halifax, D.3    Houston, J.B.4
  • 14
    • 0142010701 scopus 로고    scopus 로고
    • Drug metabolism and drug interactions:application and clinical value of in vitro models
    • Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ. Drug metabolism and drug interactions:application and clinical value of in vitro models. Curr Drug Metab 2003;4:423-459.
    • (2003) Curr Drug Metab , vol.4 , pp. 423-459
    • Venkatakrishnan, K.1    von Moltke, L.L.2    Obach, R.S.3    Greenblatt, D.J.4
  • 15
    • 0035032568 scopus 로고    scopus 로고
    • Interindividual variability in inhibition and induction of cytochrome P450 enzymes
    • Lin JH, Lu AYH. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 2001;41:535-567.
    • (2001) Annu Rev Pharmacol Toxicol , vol.41 , pp. 535-567
    • Lin, J.H.1    Lu, A.Y.H.2
  • 16
    • 0023947965 scopus 로고
    • Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985)
    • Prentis RA, Lis Y, Walker SR. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol 1988;25:387-396.
    • (1988) Br J Clin Pharmacol , vol.25 , pp. 387-396
    • Prentis, R.A.1    Lis, Y.2    Walker, S.R.3
  • 17
    • 24944547571 scopus 로고    scopus 로고
    • Why drugs fail-a study on side effects in new chemical entities
    • Schuster D, Laggner C, Langer T. Why drugs fail-a study on side effects in new chemical entities. Curr Pharm Des 2005;11:3545-3559.
    • (2005) Curr Pharm Des , vol.11 , pp. 3545-3559
    • Schuster, D.1    Laggner, C.2    Langer, T.3
  • 18
    • 0037374498 scopus 로고    scopus 로고
    • The price of innovation:new estimates of drug development costs
    • DiMasi JA, Hansen RW, Grabowski HG. The price of innovation:new estimates of drug development costs. J Health Econ 2003;22:151-185.
    • (2003) J Health Econ , vol.22 , pp. 151-185
    • DiMasi, J.A.1    Hansen, R.W.2    Grabowski, H.G.3
  • 19
    • 0043027104 scopus 로고    scopus 로고
    • In vitro drug interactions of cytochrome P450:an evaluation of fluorogenic to conventional substrates
    • Cohen LH, Remley MJ, Raunig D, Vaz ADN. In vitro drug interactions of cytochrome P450:an evaluation of fluorogenic to conventional substrates. Drug Metab Dispos 2003;31:1005-1015.
    • (2003) Drug Metab Dispos , vol.31 , pp. 1005-1015
    • Cohen, L.H.1    Remley, M.J.2    Raunig, D.3    Vaz, A.D.N.4
  • 20
    • 27644596457 scopus 로고    scopus 로고
    • Predicting in vivo drug interactions from in vitro drug discovery data
    • Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev (Drug Disco) 2005;4:825-833.
    • (2005) Nat Rev (Drug Disco) , vol.4 , pp. 825-833
    • Wienkers, L.C.1    Heath, T.G.2
  • 21
    • 33746874155 scopus 로고    scopus 로고
    • Inhibition of P450 enzymes:an in vitro approach
    • Donato MT, Gomez-Lechón MJ. Inhibition of P450 enzymes:an in vitro approach. Curr Enzyme Inhib 2006;2:281-304.
    • (2006) Curr Enzyme Inhib , vol.2 , pp. 281-304
    • Donato, M.T.1    Gomez-Lechón, M.J.2
  • 22
    • 6344250770 scopus 로고    scopus 로고
    • 57 varieties:the human cytochromes P450
    • Lewis DFV. 57 varieties:the human cytochromes P450. Pharmacogenomics 2004; 5(3):305-318.
    • (2004) Pharmacogenomics , vol.5 , Issue.3 , pp. 305-318
    • Lewis, D.F.V.1
  • 23
    • 28144458592 scopus 로고    scopus 로고
    • Simultaneous measurement of 23 isoforms from the human cytochrome P450 families 1 to 3 by quantitative reverse transcriptase-polymerase chain reaction
    • Girault I, Rougier N, Chesné C, Lideraue R, Beaune P, Biéche I, De Waziers I. Simultaneous measurement of 23 isoforms from the human cytochrome P450 families 1 to 3 by quantitative reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 2005;33:1803-1810.
    • (2005) Drug Metab Dispos , vol.33 , pp. 1803-1810
    • Girault, I.1    Rougier, N.2    Chesné, C.3    Lideraue, R.4    Beaune, P.5    Biéche, I.6    De Waziers, I.7
  • 24
    • 0032456884 scopus 로고    scopus 로고
    • Clinically important pharmacokinetic drug-drug interactions:role of cytochrome P450 enzymes
    • Tanaka E. Clinically important pharmacokinetic drug-drug interactions:role of cytochrome P450 enzymes. J Clin Pharm Ther 1998;23:403-416.
    • (1998) J Clin Pharm Ther , vol.23 , pp. 403-416
    • Tanaka, E.1
  • 25
    • 0030935086 scopus 로고    scopus 로고
    • Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
    • Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokin 1997;32(3):210-258.
    • (1997) Clin Pharmacokin , vol.32 , Issue.3 , pp. 210-258
    • Bertz, R.J.1    Granneman, G.R.2
  • 26
    • 0028237729 scopus 로고
    • Interindividual variations in human liver cytochrome P450 enzymes involved in oxidation of drugs, carcinogens and toxic chemicals;studies with liver microsomes of 30 Japanese and 30 Caucasians
    • Shimada T, Yamazaki H, Mimura M, Yukiharu I, Guengerich FP. Interindividual variations in human liver cytochrome P450 enzymes involved in oxidation of drugs, carcinogens and toxic chemicals;studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423.
    • (1994) J Pharmacol Exp Ther , vol.270 , pp. 414-423
    • Shimada, T.1    Yamazaki, H.2    Mimura, M.3    Yukiharu, I.4    Guengerich, F.P.5
  • 27
    • 0033972441 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 inhibition
    • Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 inhibition. Clin Pharmacokinet 2000; 38(1):41-57.
    • (2000) Clin Pharmacokinet , vol.38 , Issue.1 , pp. 41-57
    • Dresser, G.K.1    Spence, J.D.2    Bailey, D.G.3
  • 28
    • 32544453841 scopus 로고    scopus 로고
    • Cytochrome P450 enzymes and drug-drug interactions:an update on the superfamily
    • Lewis JD, Bachmann KA. Cytochrome P450 enzymes and drug-drug interactions:an update on the superfamily. J Pharm Technol 2006;22:22-31.
    • (2006) J Pharm Technol , vol.22 , pp. 22-31
    • Lewis, J.D.1    Bachmann, K.A.2
  • 29
  • 30
    • 10044260714 scopus 로고    scopus 로고
    • Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism
    • Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther 2004;76(6):598-606.
    • (2004) Clin Pharmacol Ther , vol.76 , Issue.6 , pp. 598-606
    • Granfors, M.T.1    Backman, J.T.2    Neuvonen, M.3    Neuvonen, P.J.4
  • 31
    • 0036219021 scopus 로고    scopus 로고
    • Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions:an update
    • Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions:an update. Curr Drug Metab 2002;3:13-37.
    • (2002) Curr Drug Metab , vol.3 , pp. 13-37
    • Hemeryck, A.1    Belpaire, F.M.2
  • 32
    • 0029893339 scopus 로고    scopus 로고
    • Influence of fluvoxamine on tacrine metabolism in vitro:potential implication for hepatotoxicity in vivo
    • Becquemont L, Bot MA, Le Riche C, Beaune P. Influence of fluvoxamine on tacrine metabolism in vitro:potential implication for hepatotoxicity in vivo. Fundam Clin Pharmacol 1996;10(2):156-157.
    • (1996) Fundam Clin Pharmacol , vol.10 , Issue.2 , pp. 156-157
    • Becquemont, L.1    Bot, M.A.2    Le Riche, C.3    Beaune, P.4
  • 34
    • 0025264682 scopus 로고
    • Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers
    • Veronese ME, Miners JO, Randles D, Gregov D, Birkett DJ. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 1990;47:403-411.
    • (1990) Clin Pharmacol Ther , vol.47 , pp. 403-411
    • Veronese, M.E.1    Miners, J.O.2    Randles, D.3    Gregov, D.4    Birkett, D.J.5
  • 35
    • 0027439883 scopus 로고
    • Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium
    • Crussell-Porter LL, Rindone JP, Ford MA, Jaskar DW. Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium. Arch Intern Med 1993;153(1):102-104.
    • (1993) Arch Intern Med , vol.153 , Issue.1 , pp. 102-104
    • Crussell-Porter, L.L.1    Rindone, J.P.2    Ford, M.A.3    Jaskar, D.W.4
  • 37
    • 0033123238 scopus 로고    scopus 로고
    • i and dangers associated with high clearance drugs in general
    • i and dangers associated with high clearance drugs in general. J Pharm Pharm Sci 1999;2(2):47-52.
    • (1999) J Pharm Pharm Sci , vol.2 , Issue.2 , pp. 47-52
    • Boxenbaum, H.1
  • 38
    • 0026671408 scopus 로고
    • Changes in the pharmacokinetics and electrocardiograph pharmacodynamics of terfenadine with concomitant administration of erythromycin
    • Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR, Jr. Changes in the pharmacokinetics and electrocardiograph pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52(3):231-238.
    • (1992) Clin Pharmacol Ther , vol.52 , Issue.3 , pp. 231-238
    • Honig, P.K.1    Woosley, R.L.2    Zamani, K.3    Conner, D.P.4    Cantilena, L.R.5
  • 40
    • 0023929374 scopus 로고    scopus 로고
    • Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients
    • Corpier CL, Jones PH, Suki WN, Lederer ED, Quinones MA, Schmidt SW, Young JB. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA 1998;260(2):239-241.
    • (1998) JAMA , vol.260 , Issue.2 , pp. 239-241
    • Corpier, C.L.1    Jones, P.H.2    Suki, W.N.3    Lederer, E.D.4    Quinones, M.A.5    Schmidt, S.W.6    Young, J.B.7
  • 42
    • 0031670167 scopus 로고    scopus 로고
    • Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
    • Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998;64(2):177-182.
    • (1998) Clin Pharmacol Ther , vol.64 , Issue.2 , pp. 177-182
    • Kantola, T.1    Kivisto, K.T.2    Neuvonen, P.J.3
  • 43
    • 0033924849 scopus 로고    scopus 로고
    • Drug interactions with cisapride:clinical implications
    • Michalets EL, Williams CR. Drug interactions with cisapride:clinical implications. Clin Pharmacokinet 2000;39(1):49-75.
    • (2000) Clin Pharmacokinet , vol.39 , Issue.1 , pp. 49-75
    • Michalets, E.L.1    Williams, C.R.2
  • 45
    • 0031802051 scopus 로고    scopus 로고
    • Pharmacokinetic interaction between oral cyclosporin and mibefradil in stabilized post-renal-transplant patients
    • Spoendlin M, Peters J, Welker H, Bock A, Thiel G. Pharmacokinetic interaction between oral cyclosporin and mibefradil in stabilized post-renal-transplant patients. Nephrol Dial Transplant 1998;13:1787-1791.
    • (1998) Nephrol Dial Transplant , vol.13 , pp. 1787-1791
    • Spoendlin, M.1    Peters, J.2    Welker, H.3    Bock, A.4    Thiel, G.5
  • 46
    • 0029664974 scopus 로고    scopus 로고
    • The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam
    • Olkkola KT, Ahonen J, Neuvonen PJ. The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996;82(3):511-516.
    • (1996) Anesth Analg , vol.82 , Issue.3 , pp. 511-516
    • Olkkola, K.T.1    Ahonen, J.2    Neuvonen, P.J.3
  • 47
    • 0031658907 scopus 로고    scopus 로고
    • Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions
    • Muck W. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs 1998;56(1s):15-23.
    • (1998) Drugs , vol.56 , Issue.1 , pp. 15-23
    • Muck, W.1
  • 48
    • 0031969657 scopus 로고    scopus 로고
    • Influence of erythromycin preand co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin
    • Muck W, Ochmann K, Rohde G, Unger S, Kuhlmann J. Influence of erythromycin preand co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacol 1998;53:469-473.
    • (1998) Eur J Clin Pharmacol , vol.53 , pp. 469-473
    • Muck, W.1    Ochmann, K.2    Rohde, G.3    Unger, S.4    Kuhlmann, J.5
  • 50
    • 0033745108 scopus 로고    scopus 로고
    • Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin
    • Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000;68:391-400.
    • (2000) Clin Pharmacol Ther , vol.68 , pp. 391-400
    • Mazzu, A.L.1    Lasseter, K.C.2    Shamblen, E.C.3    Agarwal, V.4    Lettieri, J.5    Sundaresen, P.6
  • 51
    • 33748042671 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A(HMG-CoA) reductase inhibitors:drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions
    • Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A(HMG-CoA) reductase inhibitors:drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006;112(1):71-105.
    • (2006) Pharmacol Ther , vol.112 , Issue.1 , pp. 71-105
    • Shitara, Y.1    Sugiyama, Y.2
  • 52
    • 4644301418 scopus 로고    scopus 로고
    • Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin:analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfi-brozil
    • Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin:analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfi-brozil. J Pharmacol Exp Ther 2004;311:228-236.
    • (2004) J Pharmacol Exp Ther , vol.311 , pp. 228-236
    • Shitara, Y.1    Hirano, M.2    Sato, H.3    Sugiyama, Y.4
  • 53
    • 33845420011 scopus 로고    scopus 로고
    • Drug interactions with lipid-lowering drugs:mechanisms and clinical relevance
    • Neuvonen PJ, Mikko Niemi M, Backman JT. Drug interactions with lipid-lowering drugs:mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80(6):565-581.
    • (2006) Clin Pharmacol Ther , vol.80 , Issue.6 , pp. 565-581
    • Neuvonen, P.J.1    Mikko Niemi, M.2    Backman, J.T.3
  • 55
    • 0033049626 scopus 로고    scopus 로고
    • Metabolism of some "second "-and "fourth "-generation antidepressants:iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine
    • Rotzinger S, Bourin M, Akimoto Y, Coutts RT, Bake GB. Metabolism of some "second "-and "fourth "-generation antidepressants:iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell Mol Neurobiol 1999;19(4):427-442.
    • (1999) Cell Mol Neurobiol , vol.19 , Issue.4 , pp. 427-442
    • Rotzinger, S.1    Bourin, M.2    Akimoto, Y.3    Coutts, R.T.4    Bake, G.B.5
  • 56
    • 23044500208 scopus 로고    scopus 로고
    • CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions
    • Galetin A, Ito K, Halifax D, Houston JB. CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 2005; 314(1):180-190.
    • (2005) J Pharmacol Exp Ther , vol.314 , Issue.1 , pp. 180-190
    • Galetin, A.1    Ito, K.2    Halifax, D.3    Houston, J.B.4
  • 57
    • 0033026601 scopus 로고    scopus 로고
    • Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors:an in vitro investigation with human liver preparations
    • Prueksaritanont T, Ma B, Tang C, Meng Y, Assang C, Lu P, Reider PJ, Lin JH, Baillie TA. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors:an in vitro investigation with human liver preparations. Br J Clin Pharmacol 1999;47(3):291-298.
    • (1999) Br J Clin Pharmacol , vol.47 , Issue.3 , pp. 291-298
    • Prueksaritanont, T.1    Ma, B.2    Tang, C.3    Meng, Y.4    Assang, C.5    Lu, P.6    Reider, P.J.7    Lin, J.H.8    Baillie, T.A.9
  • 58
    • 0033863264 scopus 로고    scopus 로고
    • Mibefradil is a P-glycoprotein substrate and a potent inhibitor of P-glycoprotein and CYP3A4 in vitro
    • Wandel C, Kim RB, Guengerich PF, Wood AJJ. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of P-glycoprotein and CYP3A4 in vitro. Drug Metab Dispos 2000;28:895-898.
    • (2000) Drug Metab Dispos , vol.28 , pp. 895-898
    • Wandel, C.1    Kim, R.B.2    Guengerich, P.F.3    Wood, A.J.J.4
  • 59
    • 33750982754 scopus 로고    scopus 로고
    • Drug interactions:regulatory perspective
    • Piscitelle S, Rodvold K, Eds, 2nd eds. Totowa, NJ:Humana Press
    • Reynolds KS. Drug interactions:regulatory perspective. In Piscitelle S, Rodvold K, Eds. Drug Interactions in Infectious Diseases, 2nd eds. Totowa, NJ:Humana Press; 2005.
    • (2005) Drug Interactions in Infectious Diseases
    • Reynolds, K.S.1
  • 60
    • 0034004083 scopus 로고    scopus 로고
    • Effects of the antifungal agents on oxidative drug metabolism:clinical relevance
    • Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism:clinical relevance. Clin Pharmacokinet 2000;8(2):111-180.
    • (2000) Clin Pharmacokinet , vol.8 , Issue.2 , pp. 111-180
    • Venkatakrishnan, K.1    von Moltke, L.L.2    Greenblatt, D.J.3
  • 62
    • 0028929645 scopus 로고
    • Metabolism of theophylline by cDNA-expressed human cytochromes P-450
    • Ha HR, Chen J, Freiburghaus AU, Follath F. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 1995;39(3):321-326.
    • (1995) Br J Clin Pharmacol , vol.39 , Issue.3 , pp. 321-326
    • Ha, H.R.1    Chen, J.2    Freiburghaus, A.U.3    Follath, F.4
  • 63
    • 0027515143 scopus 로고
    • Acetylation phenotype and cytochrome P450IA2 phenotype are unlikely to be associated with peripheral arterial disease
    • Ilett KF, Castleden WM, Vandongen YK, Stacey MC, Butler MA, Kadlubar FF. Acetylation phenotype and cytochrome P450IA2 phenotype are unlikely to be associated with peripheral arterial disease. Clin Pharmacol Ther 1993;54(3):317-322.
    • (1993) Clin Pharmacol Ther , vol.54 , Issue.3 , pp. 317-322
    • Ilett, K.F.1    Castleden, W.M.2    Vandongen, Y.K.3    Stacey, M.C.4    Butler, M.A.5    Kadlubar, F.F.6
  • 64
    • 33845333337 scopus 로고    scopus 로고
    • Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs
    • Dorado P, Berecz R, Penas-Lledo EM, Caceres MC, Llerena A. Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs. Curr Drug Targets 2006;7(12):1671-1680.
    • (2006) Curr Drug Targets , vol.7 , Issue.12 , pp. 1671-1680
    • Dorado, P.1    Berecz, R.2    Penas-Lledo, E.M.3    Caceres, M.C.4    Llerena, A.5
  • 65
    • 85052181068 scopus 로고
    • Cytochrome P450 enzymes and psychopharmacology
    • Bloom FE, Kupfer DJ, Eds, 4threv ed. Philadelphia:Raven Press
    • Preskorn SH, Harvey AT. Cytochrome P450 enzymes and psychopharmacology. In Bloom FE, Kupfer DJ, Eds. Psychopharmacology-The Fourth Generation of Progress, 4threv ed. Philadelphia:Raven Press; 1995.
    • (1995) Psychopharmacology-The Fourth Generation of Progress
    • Preskorn, S.H.1    Harvey, A.T.2
  • 66
    • 0035193493 scopus 로고    scopus 로고
    • Multisite kinetic models for CYP3A4:simultaneous activation and inhibition of diazepam and testosterone metabolism
    • Kenworthy KE, Clarke SE, Andrews J, Houston JB. Multisite kinetic models for CYP3A4:simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos 2001;29(12):1644-1651.
    • (2001) Drug Metab Dispos , vol.29 , Issue.12 , pp. 1644-1651
    • Kenworthy, K.E.1    Clarke, S.E.2    Andrews, J.3    Houston, J.B.4
  • 67
    • 0034956877 scopus 로고    scopus 로고
    • Dapsone activation of CYP2C9-mediated metabolism:evidence for activation of multiple substrates and a two-site model
    • Hutzler JM, Hauer MJ, Tracy TS. Dapsone activation of CYP2C9-mediated metabolism:evidence for activation of multiple substrates and a two-site model. Drug Metab Dispos 2001;29(7):1029-1034.
    • (2001) Drug Metab Dispos , vol.29 , Issue.7 , pp. 1029-1034
    • Hutzler, J.M.1    Hauer, M.J.2    Tracy, T.S.3
  • 68
    • 27544497701 scopus 로고    scopus 로고
    • Prediction of CYP2C9-mediated drug-drug interactions:a comparison using data from recombinant enzymes and human hepatocytes
    • McGinnity DF, Tucker J, Trigg S, Riley RJ. Prediction of CYP2C9-mediated drug-drug interactions:a comparison using data from recombinant enzymes and human hepatocytes. Drug Metab Dispos 2005;33(11):1700-1707.
    • (2005) Drug Metab Dispos , vol.33 , Issue.11 , pp. 1700-1707
    • McGinnity, D.F.1    Tucker, J.2    Trigg, S.3    Riley, R.J.4
  • 70
    • 0037799740 scopus 로고    scopus 로고
    • In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine
    • Egnell A-C, Houston B, Boyer S. In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J Pharmacol Exp Ther 2003;305(3):1251-1262.
    • (2003) J Pharmacol Exp Ther , vol.305 , Issue.3 , pp. 1251-1262
    • Egnell, A.-C.1    Houston, B.2    Boyer, S.3
  • 71
    • 19944393579 scopus 로고    scopus 로고
    • Enzyme kinetics for clinically relevant CYP inhibition
    • Zhang Z, Wong YN. Enzyme kinetics for clinically relevant CYP inhibition. Curr Drug Metab 2005;6:241-257.
    • (2005) Curr Drug Metab , vol.6 , pp. 241-257
    • Zhang, Z.1    Wong, Y.N.2
  • 72
    • 3042608648 scopus 로고    scopus 로고
    • Modelling kinetic data from in vitro drug metabolising enzyme experiments
    • Tracy TS, Hummell MA. Modelling kinetic data from in vitro drug metabolising enzyme experiments. Drug Metab Rev 2004;26(2):231-242.
    • (2004) Drug Metab Rev , vol.26 , Issue.2 , pp. 231-242
    • Tracy, T.S.1    Hummell, M.A.2
  • 74
    • 0036226707 scopus 로고    scopus 로고
    • Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes
    • Hollenberg PF. Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab Rev 2002;34(1-2):17-35.
    • (2002) Drug Metab Rev , vol.34 , Issue.1-2 , pp. 17-35
    • Hollenberg, P.F.1
  • 77
    • 0001842796 scopus 로고
    • Mechanism-based enzyme inactivation
    • Boca Raton, FL:CRC Press
    • Silverman RB. Mechanism-based enzyme inactivation. In Chemistry and Enzymology, Vol 1. Boca Raton, FL:CRC Press; 1988, pp 3-30.
    • (1988) Chemistry and Enzymology , vol.1 , pp. 3-30
    • Silverman, R.B.1
  • 78
    • 0021875282 scopus 로고
    • Kinetics of suicide substrates:practical procedures for determining parameters
    • Waley SG. Kinetics of suicide substrates:practical procedures for determining parameters. Biochem J 1985;227:843-849.
    • (1985) Biochem J , vol.227 , pp. 843-849
    • Waley, S.G.1
  • 79
    • 33645980647 scopus 로고    scopus 로고
    • A critical evaluation of the experimental design of studies of mechanism-based enzyme inhibition, with implications for in vitro-in vivo extrapolation
    • Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, Rostami-Hodjegan A. A critical evaluation of the experimental design of studies of mechanism-based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr Drug Metab 2006;7:315-334.
    • (2006) Curr Drug Metab , vol.7 , pp. 315-334
    • Ghanbari, F.1    Rowland-Yeo, K.2    Bloomer, J.C.3    Clarke, S.E.4    Lennard, M.S.5    Tucker, G.T.6    Rostami-Hodjegan, A.7
  • 80
    • 1942455361 scopus 로고    scopus 로고
    • Database analyses for the prediction of in vivo drug-drug interactions from in vitro data
    • Ito K, Brown HS, Houston JB. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 2004;57(4):473-486.
    • (2004) Br J Clin Pharmacol , vol.57 , Issue.4 , pp. 473-486
    • Ito, K.1    Brown, H.S.2    Houston, J.B.3
  • 81
    • 33845473315 scopus 로고    scopus 로고
    • Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction
    • Martignoni M, Groothuis GMM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2006;2(6):875-894.
    • (2006) Expert Opin Drug Metab Toxicol , vol.2 , Issue.6 , pp. 875-894
    • Martignoni, M.1    Groothuis, G.M.M.2    De Kanter, R.3
  • 82
    • 0029416939 scopus 로고
    • N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450:implications for inhibition of hemotoxicity
    • Gill HJ, Tingle MD, Park BK. N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450:implications for inhibition of hemotoxicity. Br J Clin Pharmacol 1995;40(6):531-538.
    • (1995) Br J Clin Pharmacol , vol.40 , Issue.6 , pp. 531-538
    • Gill, H.J.1    Tingle, M.D.2    Park, B.K.3
  • 83
    • 33646814927 scopus 로고    scopus 로고
    • Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5
    • Soars MG, Grime K, Riely RJ. Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5. Xenobiotica 2006;36(4):287-299.
    • (2006) Xenobiotica , vol.36 , Issue.4 , pp. 287-299
    • Soars, M.G.1    Grime, K.2    Riely, R.J.3
  • 84
    • 24944492194 scopus 로고    scopus 로고
    • Utility of recombinant cytochrome P450 enzymes:a drug metabolism perspective
    • Tang W, Wang WW, Lu AYH. Utility of recombinant cytochrome P450 enzymes:a drug metabolism perspective. Curr Drug Metab 2005;6:503-517.
    • (2005) Curr Drug Metab , vol.6 , pp. 503-517
    • Tang, W.1    Wang, W.W.2    Lu, A.Y.H.3
  • 85
    • 1542344547 scopus 로고    scopus 로고
    • Predicting drug clearance from recombinantly expressed CYPs:intersystem extrapolation factors
    • Proctor NJ, Tucker GT, Rostami-Hodjegan A. Predicting drug clearance from recombinantly expressed CYPs:intersystem extrapolation factors. Xenobiotica 2004;34(2):151-178.
    • (2004) Xenobiotica , vol.34 , Issue.2 , pp. 151-178
    • Proctor, N.J.1    Tucker, G.T.2    Rostami-Hodjegan, A.3
  • 86
    • 0034956777 scopus 로고    scopus 로고
    • Predicting drug pharmacokinetics in humans from in vitro metabolism studies
    • McGinnity DF, Riley RJ. Predicting drug pharmacokinetics in humans from in vitro metabolism studies. Biochem Soc Transact 2001;29(2):135-139.
    • (2001) Biochem Soc Transact , vol.29 , Issue.2 , pp. 135-139
    • McGinnity, D.F.1    Riley, R.J.2
  • 87
    • 4644341747 scopus 로고    scopus 로고
    • Human hepatocytes in primary culture:the choice to investigated drug metabolism in man
    • Gomez-Lechón MJ, Donato MT, Castell JV, Jover R. Human hepatocytes in primary culture:the choice to investigated drug metabolism in man. Curr Drug Metab 2004;5:443-462.
    • (2004) Curr Drug Metab , vol.5 , pp. 443-462
    • Gomez-Lechón, M.J.1    Donato, M.T.2    Castell, J.V.3    Jover, R.4
  • 88
    • 33645961595 scopus 로고    scopus 로고
    • The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions
    • Grime K, Riley RJ. The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr Drug Metab 2006;7(3):251-264.
    • (2006) Curr Drug Metab , vol.7 , Issue.3 , pp. 251-264
    • Grime, K.1    Riley, R.J.2
  • 89
    • 2042504362 scopus 로고    scopus 로고
    • Comparison of fresh and cryopreserved rat hepatocyte suspensions for the prediction of in vitro intrinsic clearance
    • Griffin SJ, Houston JB. Comparison of fresh and cryopreserved rat hepatocyte suspensions for the prediction of in vitro intrinsic clearance. Drug Metab Dispos 2004;32:552-558.
    • (2004) Drug Metab Dispos , vol.32 , pp. 552-558
    • Griffin, S.J.1    Houston, J.B.2
  • 90
    • 0344333422 scopus 로고    scopus 로고
    • Prediction of hepatic clearance from microsomes, hepatocytes and liver slices
    • Houston JB, Carlile DJ. Prediction of hepatic clearance from microsomes, hepatocytes and liver slices. Drug Metab Rev 1997;29:891-922.
    • (1997) Drug Metab Rev , vol.29 , pp. 891-922
    • Houston, J.B.1    Carlile, D.J.2
  • 91
    • 10644271665 scopus 로고    scopus 로고
    • Induction of cytochromes P450
    • Dickins M. Induction of cytochromes P450. Curr Top Med Chem 2004;4(16):1745-1766.
    • (2004) Curr Top Med Chem , vol.4 , Issue.16 , pp. 1745-1766
    • Dickins, M.1
  • 92
    • 0034964158 scopus 로고    scopus 로고
    • Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation
    • LeCluyse EL. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 2001;13(4):343-368.
    • (2001) Eur J Pharm Sci , vol.13 , Issue.4 , pp. 343-368
    • LeCluyse, E.L.1
  • 93
    • 7744225213 scopus 로고    scopus 로고
    • An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes
    • Oleson FB, Berman CL, Li AP. An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chem Biol Interact 2004;150:137-147.
    • (2004) Chem Biol Interact , vol.150 , pp. 137-147
    • Oleson, F.B.1    Berman, C.L.2    Li, A.P.3
  • 94
    • 0032968777 scopus 로고    scopus 로고
    • Cryopreserved human hepatocytes:characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential
    • Li AP, Lu C, Brent JA, Pham C, Fackett A, Ruegg CE, Silber PM. Cryopreserved human hepatocytes:characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem Biol Interact 1999;121:17-35.
    • (1999) Chem Biol Interact , vol.121 , pp. 17-35
    • Li, A.P.1    Lu, C.2    Brent, J.A.3    Pham, C.4    Fackett, A.5    Ruegg, C.E.6    Silber, P.M.7
  • 95
    • 33746047547 scopus 로고    scopus 로고
    • Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes
    • McGinnity DF, Berry AJ, Kenny JR, Grime K, Riley RJ. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab Dispos 2006;34:1291-1300.
    • (2006) Drug Metab Dispos , vol.34 , pp. 1291-1300
    • McGinnity, D.F.1    Berry, A.J.2    Kenny, J.R.3    Grime, K.4    Riley, R.J.5
  • 96
    • 18844445670 scopus 로고    scopus 로고
    • Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes
    • Zhao P, Kunze KL, Lee CA. Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab Dispos 2005;33:853-861.
    • (2005) Drug Metab Dispos , vol.33 , pp. 853-861
    • Zhao, P.1    Kunze, K.L.2    Lee, C.A.3
  • 98
    • 27544446643 scopus 로고    scopus 로고
    • Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis
    • Atkinson A, Kenny JR, Grime K. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab Dispos 2005;33:1637-1647.
    • (2005) Drug Metab Dispos , vol.33 , pp. 1637-1647
    • Atkinson, A.1    Kenny, J.R.2    Grime, K.3
  • 99
    • 0028078626 scopus 로고
    • Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450:inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid
    • Lopez-Garcia MP, Dansette PM, Mansuy D. Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450:inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry 1994;33(1):166-175.
    • (1994) Biochemistry , vol.33 , Issue.1 , pp. 166-175
    • Lopez-Garcia, M.P.1    Dansette, P.M.2    Mansuy, D.3
  • 100
    • 0033831197 scopus 로고    scopus 로고
    • An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation
    • Mayhew BS, Jones DR, Hall SD. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 2000;28:1031-1037.
    • (2000) Drug Metab Dispos , vol.28 , pp. 1031-1037
    • Mayhew, B.S.1    Jones, D.R.2    Hall, S.D.3
  • 101
    • 0034634252 scopus 로고    scopus 로고
    • Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4
    • Chan WK, Delucchi AB. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 2000;67(25):3103-3112.
    • (2000) Life Sci , vol.67 , Issue.25 , pp. 3103-3112
    • Chan, W.K.1    Delucchi, A.B.2
  • 102
    • 0034089555 scopus 로고    scopus 로고
    • Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4
    • Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res 2000;17(4):419-426.
    • (2000) Pharm Res , vol.17 , Issue.4 , pp. 419-426
    • Kanamitsu, S.1    Ito, K.2    Green, C.E.3    Tyson, C.A.4    Shimada, N.5    Sugiyama, Y.6
  • 103
    • 0035064595 scopus 로고    scopus 로고
    • Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo / in vitro absorption, distribution, and metabolism data
    • Yamano K, Yamamoto K, Katashima M, Kotaki H, Takedomi S, Matsuo H, Ohtani H, Sawada Y, Iga T. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo / in vitro absorption, distribution, and metabolism data. Drug Metab Dispos 2001;29(4):443-452.
    • (2001) Drug Metab Dispos , vol.29 , Issue.4 , pp. 443-452
    • Yamano, K.1    Yamamoto, K.2    Katashima, M.3    Kotaki, H.4    Takedomi, S.5    Matsuo, H.6    Ohtani, H.7    Sawada, Y.8    Iga, T.9
  • 104
    • 0038311984 scopus 로고    scopus 로고
    • Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes
    • Ito K, Ogihara K, Kanamitsu S, Itoh T. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 2003;31(7):945-954.
    • (2003) Drug Metab Dispos , vol.31 , Issue.7 , pp. 945-954
    • Ito, K.1    Ogihara, K.2    Kanamitsu, S.3    Itoh, T.4
  • 105
    • 18844388453 scopus 로고    scopus 로고
    • Metabolism-dependent P450 3A4 inactivation with multiple substrates. Abstract from 12th North American ISSX Meeting, Providence, RI
    • Dai R, Wei X, Luo G, Sinz M, Marathe P. Metabolism-dependent P450 3A4 inactivation with multiple substrates. Abstract from 12th North American ISSX Meeting, Providence, RI. Drug Metab Rev 2003;35:341.
    • (2003) Drug Metab Rev , vol.35 , pp. 341
    • Dai, R.1    Wei, X.2    Luo, G.3    Sinz, M.4    Marathe, P.5
  • 106
    • 1942421316 scopus 로고    scopus 로고
    • Integrating in vitro kinetic data from compounds exhibiting induction, reversible inhibition and mechanism-based inactivation:in vitro study design
    • McConn DJ, Zhao Z. Integrating in vitro kinetic data from compounds exhibiting induction, reversible inhibition and mechanism-based inactivation:in vitro study design. Curr Drug Metab 2004;5:141-146.
    • (2004) Curr Drug Metab , vol.5 , pp. 141-146
    • McConn, D.J.1    Zhao, Z.2
  • 107
    • 0031810018 scopus 로고    scopus 로고
    • Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples
    • Boobis AR, McKillop D, Robinson DT, Adams DA, McCormick DJ. Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples. Xenobiotica 1998;28(5):493-506.
    • (1998) Xenobiotica , vol.28 , Issue.5 , pp. 493-506
    • Boobis, A.R.1    McKillop, D.2    Robinson, D.T.3    Adams, D.A.4    McCormick, D.J.5
  • 108
    • 0032733974 scopus 로고    scopus 로고
    • Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data:an examination of in vitro half-life approach and non-specific binding to microsomes
    • Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data:an examination of in vitro half-life approach and non-specific binding to microsomes. Drug Metab Dispos 1999;27:1350-1359.
    • (1999) Drug Metab Dispos , vol.27 , pp. 1350-1359
    • Obach, R.S.1
  • 109
    • 0035154850 scopus 로고    scopus 로고
    • The potential pharmacological and toxicological impact of P450 screening
    • Riley RJ. The potential pharmacological and toxicological impact of P450 screening. Curr Opin Drug Discov Dev 2001;4:45-54.
    • (2001) Curr Opin Drug Discov Dev , vol.4 , pp. 45-54
    • Riley, R.J.1
  • 110
    • 14044251501 scopus 로고    scopus 로고
    • The binding of drugs to hepatocytes and its relastionship to physicochemical properties
    • Austin RP, Barton P, Mohmed S, Riley RJ. The binding of drugs to hepatocytes and its relastionship to physicochemical properties. Drug Metab Dispos 2005;33(3):419-425.
    • (2005) Drug Metab Dispos , vol.33 , Issue.3 , pp. 419-425
    • Austin, R.P.1    Barton, P.2    Mohmed, S.3    Riley, R.J.4
  • 111
    • 0036891948 scopus 로고    scopus 로고
    • The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties
    • Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 2002;30(12):1497-1503.
    • (2002) Drug Metab Dispos , vol.30 , Issue.12 , pp. 1497-1503
    • Austin, R.P.1    Barton, P.2    Cockroft, S.L.3    Wenlock, M.C.4    Riley, R.J.5
  • 112
    • 13244277455 scopus 로고    scopus 로고
    • Metabolic screening in vitro:metabolic stability, CYP inhibition and induction
    • Riley RJ, Grime K. Metabolic screening in vitro:metabolic stability, CYP inhibition and induction. Drug Discov Today 2004;1(4):365-372.
    • (2004) Drug Discov Today , vol.1 , Issue.4 , pp. 365-372
    • Riley, R.J.1    Grime, K.2
  • 113
    • 0034007499 scopus 로고    scopus 로고
    • Substrate-dependent effect of acetronitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity
    • Tang C, Shou M, Rodrigues AD. Substrate-dependent effect of acetronitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity. Drug Metab Dispos 2000;28:567-572.
    • (2000) Drug Metab Dispos , vol.28 , pp. 567-572
    • Tang, C.1    Shou, M.2    Rodrigues, A.D.3
  • 114
    • 33748636018 scopus 로고    scopus 로고
    • Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development
    • Baranczewski P, Stanczak A, Sundberg K, Svensson R, Wallin A, Jansson J, Garberg P, Postlind H. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep 2006;58:453-472.
    • (2006) Pharmacol Rep , vol.58 , pp. 453-472
    • Baranczewski, P.1    Stanczak, A.2    Sundberg, K.3    Svensson, R.4    Wallin, A.5    Jansson, J.6    Garberg, P.7    Postlind, H.8
  • 115
    • 2442690439 scopus 로고    scopus 로고
    • Validated assays for human cytochrome P450 activities
    • Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities. Drug Metab Dispos 2004;32:647-660.
    • (2004) Drug Metab Dispos , vol.32 , pp. 647-660
    • Walsky, R.L.1    Obach, R.S.2
  • 116
    • 0037974571 scopus 로고    scopus 로고
    • Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation
    • Weaver R, Grime K, Beatie IG, Riley RJ. Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab Dispos 2003;31:955-966.
    • (2003) Drug Metab Dispos , vol.31 , pp. 955-966
    • Weaver, R.1    Grime, K.2    Beatie, I.G.3    Riley, R.J.4
  • 117
    • 0034807892 scopus 로고    scopus 로고
    • Optimising drug development:strategies to assess drug metabolism/transport interaction potential-towards a consensus
    • Tucker GT, Houston JB, Huang S. Optimising drug development:strategies to assess drug metabolism/transport interaction potential-towards a consensus. Pharm Res 2001;18(8):1071-1080.
    • (2001) Pharm Res , vol.18 , Issue.8 , pp. 1071-1080
    • Tucker, G.T.1    Houston, J.B.2    Huang, S.3
  • 118
    • 33847416297 scopus 로고    scopus 로고
    • The development of a cocktail CYP2B6, CYP2C8 and CYP3A5 inhibition assay and a preliminary assessment of utiliy in a drug discovery setting
    • O'Donnell CJ, Grime K, Courtney P, Slee D, Riley RJ. The development of a cocktail CYP2B6, CYP2C8 and CYP3A5 inhibition assay and a preliminary assessment of utiliy in a drug discovery setting. Drug Metab Dispos 2007;35(3):381-385.
    • (2007) Drug Metab Dispos , vol.35 , Issue.3 , pp. 381-385
    • O'Donnell, C.J.1    Grime, K.2    Courtney, P.3    Slee, D.4    Riley, R.J.5
  • 119
    • 0032970480 scopus 로고    scopus 로고
    • Fully automated analysis of activities catalysed by the major human liver cytochrome P450(CYP) enzymes:assessment of human CYP inhibition potential
    • Moody GC, Griffin SJ, Mather AN, McGinnity DF, Riley RJ. Fully automated analysis of activities catalysed by the major human liver cytochrome P450(CYP) enzymes:assessment of human CYP inhibition potential. Xenobiotica 1999;29(1):53-75.
    • (1999) Xenobiotica , vol.29 , Issue.1 , pp. 53-75
    • Moody, G.C.1    Griffin, S.J.2    Mather, A.N.3    McGinnity, D.F.4    Riley, R.J.5
  • 121
    • 0035015324 scopus 로고    scopus 로고
    • High-throughput cytochrome P450(CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1
    • Bu H-Z, Magis L, Knuth K, Teitelbaum P. High-throughput cytochrome P450(CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1. Rapid Commun Mass Spectrom 2001;15(10):741-748.
    • (2001) Rapid Commun Mass Spectrom , vol.15 , Issue.10 , pp. 741-748
    • Bu, H.-Z.1    Magis, L.2    Knuth, K.3    Teitelbaum, P.4
  • 124
    • 0031028518 scopus 로고    scopus 로고
    • Cooperativity in oxidations catalyzed by cytochrome P450 3A4
    • Ueng YF, Kuwabara T, Chun YJ, Guengerich FP. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 1997;36(2):370-381.
    • (1997) Biochemistry , vol.36 , Issue.2 , pp. 370-381
    • Ueng, Y.F.1    Kuwabara, T.2    Chun, Y.J.3    Guengerich, F.P.4
  • 126
    • 0035298741 scopus 로고    scopus 로고
    • A high-capacity LC-MS system for the bioanalysis of samples generated from plate based metabolic screening
    • Janiszewski JS, Rogers KJ, Whalen KM, Cole MJ, Liston TE, Duchosiav E, Fouda HG. A high-capacity LC-MS system for the bioanalysis of samples generated from plate based metabolic screening. Anal Chem 2001;73(7):1495-1501.
    • (2001) Anal Chem , vol.73 , Issue.7 , pp. 1495-1501
    • Janiszewski, J.S.1    Rogers, K.J.2    Whalen, K.M.3    Cole, M.J.4    Liston, T.E.5    Duchosiav, E.6    Fouda, H.G.7
  • 128
    • 33846923287 scopus 로고    scopus 로고
    • In silico prediction of cytochrome P450 2D6 and 3A4 inhibition using Gaussian kernel weighted k-nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors
    • Jensen BF, Vind C, Padkjr SB, Brockhoff PB, Refsgaard HHF. In silico prediction of cytochrome P450 2D6 and 3A4 inhibition using Gaussian kernel weighted k-nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors. J Med Chem 2007;50(3):501-511.
    • (2007) J Med Chem , vol.50 , Issue.3 , pp. 501-511
    • Jensen, B.F.1    Vind, C.2    Padkjr, S.B.3    Brockhoff, P.B.4    Refsgaard, H.H.F.5
  • 130
    • 33644861762 scopus 로고    scopus 로고
    • Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions:pitfalls, progress and promise
    • Bachmann KA. Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions:pitfalls, progress and promise. Curr Drug Metab 2006;7:1-14.
    • (2006) Curr Drug Metab , vol.7 , pp. 1-14
    • Bachmann, K.A.1
  • 131
    • 85052167681 scopus 로고    scopus 로고
    • Regression analysis in design and analysis
    • Purich DL, Ed, 2nd ed. San Diego, CA:Academic Press
    • Mannervik B. Regression analysis in design and analysis. In Purich DL, Ed. Contemporary Enzyme Kinetics and Mechanism, 2nd ed. San Diego, CA:Academic Press; 1996.
    • (1996) Contemporary Enzyme Kinetics and Mechanism
    • Mannervik, B.1
  • 133
    • 0037058253 scopus 로고    scopus 로고
    • A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis "for the manifestation of idiosyncratic drug toxicity
    • Li AP. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis "for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact 2002;142(1-2):7-23.
    • (2002) Chem Biol Interact , vol.142 , Issue.1-2 , pp. 7-23
    • Li, A.P.1
  • 135
    • 0016566218 scopus 로고
    • A physiological approach to hepatic drug clearance
    • Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975;18:377-390.
    • (1975) Clin Pharmacol Ther , vol.18 , pp. 377-390
    • Wilkinson, G.R.1    Shand, D.G.2
  • 136
    • 13244287685 scopus 로고    scopus 로고
    • In silico simulations to assess the in vivo consequences of in vitro metabolic drug-drug interactions
    • Rostami-Hodjegan A, Tucker G. In silico simulations to assess the in vivo consequences of in vitro metabolic drug-drug interactions. Drug Discov Today 2004;1(4):441-448.
    • (2004) Drug Discov Today , vol.1 , Issue.4 , pp. 441-448
    • Rostami-Hodjegan, A.1    Tucker, G.2
  • 137
    • 0346992330 scopus 로고    scopus 로고
    • Progress towards prediction of human pharmacokinetic parameters from in vitro technologies
    • Houston JB, Galetin A. Progress towards prediction of human pharmacokinetic parameters from in vitro technologies. Drug Metab Rev 2003;35(4):393-415.
    • (2003) Drug Metab Rev , vol.35 , Issue.4 , pp. 393-415
    • Houston, J.B.1    Galetin, A.2
  • 138
    • 18844369894 scopus 로고    scopus 로고
    • Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions:CYP2D6 paradigm
    • Ito K, Halifax D, Obach RS, Houston JB. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions:CYP2D6 paradigm. Drug Metab Dispos 2005;33(6):837-844.
    • (2005) Drug Metab Dispos , vol.33 , Issue.6 , pp. 837-844
    • Ito, K.1    Halifax, D.2    Obach, R.S.3    Houston, J.B.4
  • 140
    • 85008414650 scopus 로고    scopus 로고
    • Evaluation of methods for predicting drug-drug interactions by Monte Carlo simulation
    • Kato M, Tachibana T, Ito K, Sugiyama Y. Evaluation of methods for predicting drug-drug interactions by Monte Carlo simulation. Drug Metab Pharmacokinet 2003;18(2):121-127.
    • (2003) Drug Metab Pharmacokinet , vol.18 , Issue.2 , pp. 121-127
    • Kato, M.1    Tachibana, T.2    Ito, K.3    Sugiyama, Y.4
  • 142
    • 23944451585 scopus 로고    scopus 로고
    • A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes
    • Riley RJ, McGinnity DF, Austin RP. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 2005;33(9):1304-1311.
    • (2005) Drug Metab Dispos , vol.33 , Issue.9 , pp. 1304-1311
    • Riley, R.J.1    McGinnity, D.F.2    Austin, R.P.3
  • 143
    • 27444445468 scopus 로고    scopus 로고
    • Prediction of in vivo drug-drug interactions from in vitro data:impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant
    • Brown HS, Ito K, Galetin A, Houston JB. Prediction of in vivo drug-drug interactions from in vitro data:impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 2005;60(5):508-518.
    • (2005) Br J Clin Pharmacol , vol.60 , Issue.5 , pp. 508-518
    • Brown, H.S.1    Ito, K.2    Galetin, A.3    Houston, J.B.4
  • 145
    • 0842282550 scopus 로고    scopus 로고
    • Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites
    • Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 2004;32(2):259-266.
    • (2004) Drug Metab Dispos , vol.32 , Issue.2 , pp. 259-266
    • Wang, Y.H.1    Jones, D.R.2    Hall, S.D.3
  • 146
    • 13244299150 scopus 로고    scopus 로고
    • Mechanism-based inactivation of CYP3A by HIV protease inhibitors
    • Ernest CS, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 2005;312(2):583-591.
    • (2005) J Pharmacol Exp Ther , vol.312 , Issue.2 , pp. 583-591
    • Ernest, C.S.1    Hall, S.D.2    Jones, D.R.3
  • 147
    • 33846449874 scopus 로고    scopus 로고
    • Mechanism based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions
    • Obach RS, Walsky RL, Venkatakrishnan K. Mechanism based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 2007;35(2):246-255.
    • (2007) Drug Metab Dispos , vol.35 , Issue.2 , pp. 246-255
    • Obach, R.S.1    Walsky, R.L.2    Venkatakrishnan, K.3
  • 148
    • 33745061875 scopus 로고    scopus 로고
    • Pharmacokinetic consequences of time-dependent inhibition using the isolated perfused rat liver model
    • Kenny JR, Grime K. Pharmacokinetic consequences of time-dependent inhibition using the isolated perfused rat liver model. Xenobiotica 2006;36(5):351-365.
    • (2006) Xenobiotica , vol.36 , Issue.5 , pp. 351-365
    • Kenny, J.R.1    Grime, K.2
  • 150
    • 0023009594 scopus 로고
    • A pharmacokinetic drug interaction between erythromycin and triazolam
    • Phillips JP, Antal EJ, Smith RB. A pharmacokinetic drug interaction between erythromycin and triazolam. J Clin Psychopharmacol 1986;6:297-299.
    • (1986) J Clin Psychopharmacol , vol.6 , pp. 297-299
    • Phillips, J.P.1    Antal, E.J.2    Smith, R.B.3
  • 151
    • 29944446485 scopus 로고    scopus 로고
    • Prediction of time-dependent CYP3A4 drug-drug interactions:impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition
    • Galetin A, Burt H, Gibbons L, Houston JB. Prediction of time-dependent CYP3A4 drug-drug interactions:impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 2006;34(1):166-175.
    • (2006) Drug Metab Dispos , vol.34 , Issue.1 , pp. 166-175
    • Galetin, A.1    Burt, H.2    Gibbons, L.3    Houston, J.B.4
  • 152
    • 33845978421 scopus 로고    scopus 로고
    • A novel method for the prediction of drug-drug interactions in humans based on in vitro CYP phenotypic data
    • Lu C, Miwa GT, Prakash SR, Gan L, Balani SK. A novel method for the prediction of drug-drug interactions in humans based on in vitro CYP phenotypic data. Drug Metab Dispos 2007;35(1):79-85.
    • (2007) Drug Metab Dispos , vol.35 , Issue.1 , pp. 79-85
    • Lu, C.1    Miwa, G.T.2    Prakash, S.R.3    Gan, L.4    Balani, S.K.5
  • 154
    • 0033948964 scopus 로고    scopus 로고
    • Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir:comparison with ketoconazole
    • von Moltke LL, Durol ALB, Duan SX, Greenblatt DJ. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir:comparison with ketoconazole. Eur J Clin Pharmacol 2000;56(3):259-261.
    • (2000) Eur J Clin Pharmacol , vol.56 , Issue.3 , pp. 259-261
    • Von Moltke, L.L.1    Durol, A.L.B.2    Duan, S.X.3    Greenblatt, D.J.4
  • 155
    • 0043127390 scopus 로고    scopus 로고
    • Rapid assessment of P-glycoprotein inhibition and induction in vitro
    • Perloff MD, Stoermer E, von Moltke LL, Greenblatt DJ. Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm Res 2003;20(8):1177-1183.
    • (2003) Pharm Res , vol.20 , Issue.8 , pp. 1177-1183
    • Perloff, M.D.1    Stoermer, E.2    von Moltke, L.L.3    Greenblatt, D.J.4
  • 158
    • 85052166414 scopus 로고    scopus 로고
    • US Food and Drug Administration, Center for Drug Evaluation and Research website. http://www.fda.gov/CDER.
  • 159
    • 85052181058 scopus 로고    scopus 로고
    • US Food and Drug Administration, Center for Drug Evaluation and Research website. Guidance web page. http://www.fda.gov/CDER/guidance.
    • Guidance web page


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.